Relugolix is the first and only, orally-administered GnRH receptor antagonist approved for the treatment of several hormone-responsive conditions, including prostate cancer - similar therapies require subcutaneous administration - and therefore provides a less burdensome therapeutic option for patients
| Product Name |
Relugolix |
| CAS Number |
737789-87-6 |
| Therapeutic Class |
Anti-endometriosis, Antineoplastic |
| Dosage Form |
Oral Tablet |
| Availability |
Under Evaluation |
| Regulatory Status |
|